Importance of clinical, radiological and functional methods of investigation for diagnosis and assessment of the efficiency of treatment of Langerhans' cell histiocytosis Source: Eur Respir J 2001; 18: Suppl. 33, 383s Year: 2001
Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019
A role for ITPA variants in the clinical course of pulmonary Langerhans' cell histiocytosis? Source: Eur Respir J 2010; 36: 684-686 Year: 2010
Pulmonary Langerhans histiocytosis: clinical, radiological and functional pattern in spontaneous remission Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009
Langerhans cell histiocytosis: is it an ILD? Source: Virtual Congress 2021 – Interstitial lung diseases Year: 2021
Clinical impact of BRAFV600E mutation in adult pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019
Exercise in patients with pulmonary Langerhans cell histiocytosis: performance and mechanisms of limitation Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017
How I manage pulmonary Langerhans cell histiocytosis Source: Eur Respir Rev, 26 (145) 170070; 10.1183/16000617.0070-2017 Year: 2017
Multisystemic Langerhans cell histiocytosis unresponsive to aggressive chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 383s Year: 2006
Chemotherapy in patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2018 – Progress in rare interstitial lung diseases Year: 2018
Pulmonary Langerhans' cell histiocytosis Source: Eur Respir Mon; 2009: 46: 155–175 Year: 2009
Clinical and pathological features of 13 adult patients with pulmonary Langerhans‘ cell histiocytosis Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009
Effectiveness of chemotherapy treatment for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Langerhans’ cell granulomatosis: clinical manifestations and prognosis of pulmonary lesions Source: Eur Respir J 2004; 24: Suppl. 48, 49s Year: 2004
Psychological abnormalities are commonly present in adult patients with pulmonary Langerhans cell histiocytosis Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment Year: 2019
Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019
Pulmonary Langerhans' cell histiocytosis Source: Respipedia Article Year: 2016
Do high resolution CT findings predict lung function impairment in pulmonary Langerhans cell histiocytosis? Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002
The proteomic analysis of BAL from patients with langerhans cell histiocytosis (LCH) Source: Eur Respir J 2007; 30: Suppl. 51, 245s Year: 2007
Genetic landscape of adult Langerhans cell histiocytosis with lung involvement Source: Eur Respir J, 55 (2) 1901190; 10.1183/13993003.01190-2019 Year: 2020